EXELIXIS INC (EXEL) Stock News
NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock
EXEL Latest News and Analysis
First Week of March 21st Options Trading For Exelixis (EXEL)
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying.
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
First Week of August 2025 Options Trading For Exelixis (EXEL)
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
/PRNewswire/ -- Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc....
2 Biotech Stocks to Buy Hand Over Fist in December
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects.
2 Biotech Stocks to Buy Hand Over Fist in December
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks.
